Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Normanno N"'
Autor:
Ettore Capoluongo, Sandro Pignata, Paola Carrera, Enrico Ricevuto, Maurizio Genuardi, Paolo Radice, Antonio Russo, Nicoletta Colombo, Carmine Pinto, Stefania Gori, Barbara Pasini, Paolo Marchetti, Nicola Normanno, Valentina Guarneri, Laura Cortesi, Antonio Marchetti, Mauro Truini, Maria Angela Bella, Pierosandro Tagliaferri, Pierfrancesco Tassone, Gaetano De Rosa, Francesca Fenizia, Claudio Clemente, Liliana Varesco
In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb9b4ad22ad35cde975131fad7a5a30
http://hdl.handle.net/11577/3362422
http://hdl.handle.net/11577/3362422
Autor:
Teresa Troiani, Giulia Martini, F. De Vita, Claudia Cardone, Tiziana Latiano, Fortunato Ciardiello, Evaristo Maiello, Nicola Normanno, Erika Martinelli, Anna Maria Rachiglio, Pietro Paolo Vitiello, Davide Ciardiello
Epidermal growth factor receptor (EGFR) inhibitors are valuable therapeutics in metastatic colorectal cancer (mCRC). Anti-EGFR monoclonal antibodies (MoAbs), such as cetuximab or panitumumab, in combination with chemotherapy are effective treatment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc1e2145074e4fd31c7a3f556eb19ea
http://hdl.handle.net/11591/427752
http://hdl.handle.net/11591/427752
Autor:
Antonio Rossi, Francesco Perrone, Filippo de Marinis, Fortunato Ciardiello, Agnese Montanino, Cesare Gridelli, Floriana Morgillo, Nicola Normanno, Ciro Gallo, Gennaro Daniele, Lucio Crinò, Maria Carmela Piccirillo, Alessandro Morabito
Publikováno v:
Clinical Lung Cancer. 17:461-465
BACKGROUND: About 20% of advanced non-small-cell lung cancer (NSCLC) cases harbor somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene. In these patients, the standard first-line treatments are the EGFR-
Autor:
Ramon Salazar, Chiara Chianese, Evaristo Maiello, Alba Noguerido, Josep Tabernero, Ana Vivancos, Erica Martinelli, Judit Matito, Guillem Argiles, Cristina Santos, Giulia Martini, Ginevra Caratu, Jaume Capdevila, Ariadna Garcia, Francesco M. Mancuso, Julieta Grasselli, Nuria Mulet, Nicola Normanno, Fortunato Ciardello, Enrique Sanz-Garcia, Claudia Cardone, Elena Elez, Frederick S. Jones, Riziero Esposito Abate, Teresa Macarulla
Publikováno v:
Molecular Oncology
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Molecular Oncology, Vol 13, Iss 9, Pp 1827-1835 (2019)
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Molecular Oncology, Vol 13, Iss 9, Pp 1827-1835 (2019)
Metastatic colorectal cancer; RAS analysis; Prognostic biomarker Cáncer colorrectal en metástasis; Análisis RAS; Biomarcador como pronóstico Càncer colorectal en metàstasi; Anàlisi RAS; Biomarcador com a pronòstic Despite major advances in th
Autor:
Silvana Leo, A. Rinaldi, Francesco Giuliani, Salvatore Pisconti, R. Esposito Abate, Alessia Iannaccone, Fortunato Ciardiello, Matilde Lambiase, Anna Maria Rachiglio, Evaristo Maiello, E. Martinelli, Nicola Normanno, M. Biglietto, Laura Forgione, Teresa Troiani, Tiziana Latiano, Roberto Bordonaro, Claudia Cardone, D. Rizzi, Alessandra Sacco
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(1)
Background Liquid biopsy is an alternative to tissue for RAS testing in metastatic colorectal carcinoma (mCRC) patients. Little information is available on the predictive role of liquid biopsy RAS testing in patients treated with first-line anti-EGFR
Autor:
Giovanna Finocchiaro, Filippo de Marinis, Marcello Tiseo, Giulio Cerea, Alessandro Del Conte, Laura Giannetta, Maria Rita Migliorino, Rita Chiari, Marco Angelo Burgio, Francesca Mazzoni, Agnese Montanino, Alessandro Morabito, Federico Cappuzzo, Nicola Normanno, Roberta Buosi, Paolo Bidoli, Diego Cortinovis, Luisa Foltran, Silvia Ferrari
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 99
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR-tyrosine kinase inhibitors (TKI), most of them progress within 12 months fro
Autor:
Giuseppe Perrone, Mario Manusia, Erika Martinelli, Eugenio Tommaselli, Salvatore Pisconti, A. Perrino, M. Biglietto, Giuseppe Colucci, A. Cardarelli, A. Onetti Muda, Francesco Giuliani, Guido Rindi, Guglielmo Nasti, D. Rizzi, Anna Maria Rachiglio, Saverio Cinieri, Evaristo Maiello, Antonio Febbraro, Fortunato Ciardiello, Gianni Simone, Giacomo Cartenì, E. Montesarchio, Matilde Lambiase, Fabiana Tatangelo, Teresa Troiani, Nicola Normanno, G. Botti, Daniela Cabibi, A. Rinaldi, Alessia Iannaccone, Pietro Micheli, C. Barone, Oscar Nappi, Antonio Russo, Cristin Roma, Roberto Bordonaro, Claudia Esposito, Annamaria Sebastio, Francesca Fenizia, Paolo Graziano, S. Romito, Giuseppe Tonini, Pantaleo Bufo, Tiziana Latiano, Nicoletta Chicchinelli, P. Giaccone, M. Criscuolo
Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative assessment of tumor heterogeneity for KRAS, NRAS, BRAF and PIK3CA mutations, in order to assess pote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e00a8ef70d693dea7a745c8bef2ef289
http://hdl.handle.net/10447/295526
http://hdl.handle.net/10447/295526
Autor:
Sabine Tejpar, Eric Van Cutsem, Bruno Wohlschlegel, Domenica Mercadante, Nicola Normanno, T. Teague, Fortunato Ciardiello
Publikováno v:
Targeted oncology. 6(3)
The mutation status of the KRAS gene in the tumors of patients with metastatic colorectal cancer (mCRC) is a predictive biomarker for the efficacy of epidermal growth factor receptor monoclonal antibody therapy. The establishment of KRAS mutation tes
Autor:
Salvatore Siena, Marcello Gambacorta, Antonio Marchetti, Gianluigi Taddei, Gerardo Botti, Alberto Bardelli, Oscar Nappi, Fortunato Ciardiello, Nicola Normanno, Francesca Castiglione, Carmine Pinto
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e29146 (2011)
PLoS ONE
PLoS ONE
BackgroundMonoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1116be69aaf9640d6a8e0bdc824a313
http://hdl.handle.net/2318/96347
http://hdl.handle.net/2318/96347
Publikováno v:
The Lancet. Oncology. 12(6)
Summary The discovery of mutant KRAS as a predictor of resistance to epidermal growth-factor receptor (EGFR) monoclonal antibodies brought a major change in the treatment of metastatic colorectal cancer. This seminal finding also highlighted our spar